Allan Balmain

This study analyzes mouse skin tumors to determine how environmental factors like TPA, obesity, and wounding affect mutational burden and cancer risk, finding that tumor promoters, not mutation number, limit tumor growth.

The paper identifies a mouse tumor susceptibility gene signature (mTSGS) that predicts chemotherapy response in ERBB2-driven breast cancer, validated in both mouse models and human datasets.

This study identifies KRAS4A and KRAS4B splice isoforms with distinct expression patterns in cancer stem cells and shows that targeting KRAS4A splicing is a potential therapeutic strategy in KRAS mutant tumors.

The paper identifies principles for improving synthetic lethality reproducibility by integrating pathway, cellular, and genetic context in KRAS-mutant cells.